Obstet Gynecol Sci.  2018 Sep;61(5):615-620. 10.5468/ogs.2018.61.5.615.

The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer

• Lee S
• Kim YH
• Kim SC
• Joo JK
• Seo DS
• Kim KH
• Lee KS

• KMID: 2426027
• DOI: http://doi.org/10.5468/ogs.2018.61.5.615

Abstract

OBJECTIVE
To evaluate the effect of tamoxifen on female reproductive organs in women with breast cancer.
METHODS
We retrospectively reviewed the medical records of 309 women with breast cancer who were currently receiving tamoxifen and undergoing regular gynecological examination.
RESULTS
We evaluated 92 pre- and 217 postmenopausal women. The prevalence of endometrial thickening was 12% in the pre- and 10.6% in the postmenopausal group. An endometrial biopsy was performed in 43 women and confirmed endometrial cancer in 1, endometrial polyps in 14, and endometrial hyperplasia in 4 women. Transvaginal ultrasonography showed 25 cases of newly developed ovarian cysts. Most ovarian cysts had disappeared during follow-up.
CONCLUSION
Tamoxifen use in women with breast cancer causes few complications and is considered safe for female reproductive organs in case of regular gynecological examination.

Keyword

Tamoxifen; Endometrium; Breast neoplasms; Ovary

MeSH Terms

Biopsy
Breast Neoplasms*
Breast*
Endometrial Hyperplasia
Endometrial Neoplasms
Endometrium*
Female
Follow-Up Studies
Gynecological Examination
Humans
Medical Records
Ovarian Cysts*
Ovary
Polyps
Prevalence
Retrospective Studies
Tamoxifen*
Ultrasonography
Tamoxifen

Reference

1. Kim YA, Oh IH, Yoon SJ, Kim HJ, Seo HY, Kim EJ, et al. The economic burden of breast cancer in Korea from 2007–2010. Cancer Res Treat. 2015; 47:583–590.

2. American Cancer Society. Breast cancer facts & figures 2017–2018. Atlanta (GA): American Cancer Society;2017.

3. Murphy GP, Lawrence W, Lenhard RE. American Cancer Society textbook of clinical oncology. Atlanta (GA): American Cancer Society;1995.

4. Figg WD 2nd, Cook K, Clarke R. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer. Cancer Biol Ther. 2014; 15:1586–1587.

5. Le Donne M, Alibrandi A, Ciancimino L, Azzerboni A, Chiofalo B, Triolo O. Endometrial pathology in breast cancer patients: effect of different treatments on ultrasonographic, hysteroscopic and histological findings. Oncol Lett. 2013; 5:1305–1310.

6. Metindir J, Aslan S, Bilir G. Ovarian cyst formation in patients using tamoxifen for breast cancer. Jpn J Clin Oncol. 2005; 35:607–611.

7. Cheng WF, Lin HH, Torng PL, Huang SC. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 1997; 66:233–237.

8. Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJ, Cordoba M, et al. Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol. 1996; 15:152–157.

9. Sismondi P, Biglia N, Volpi E, Giai M, de Grandis T. Tamoxifen and endometrial cancer. Ann N Y Acad Sci. 1994; 734:310–321.

10. Ramondetta LM, Sherwood JB, Dunton CJ, Palazzo JP. Endometrial cancer in polyps associated with tamoxifen use. Am J Obstet Gynecol. 1999; 180:340–341.

11. Cohen I, Beyth Y, Tepper R, Shapira J, Zalel Y, Figer A, et al. Ovarian tumors in postmenopausal breast cancer patients treated with tamoxifen. Gynecol Oncol. 1996; 60:54–58.

12. Seoud MA, Johnson J, Weed JC Jr. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 1993; 82:165–169.

13. Gerber B, Krause A, Müller H, Reimer T, Külz T, Makovitzky J, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol. 2000; 18:3464–3470.

14. Cohen I, Azaria R, Shapira J, Yigael D, Tepper R. Significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women. Cancer. 2002; 94:3101–3106.

15. Kim HS, Jeon YT, Kim YB. The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients. J Gynecol Oncol. 2008; 19:256–260.

16. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004; 94:256–266.

17. Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol. 2000; 78:181–186.

18. Jolles CJ, Smotkin D, Ford KL, Jones KP. Cystic ovarian necrosis complicating tamoxifen therapy for breast cancer in a premenopausal woman. A case report. J Reprod Med. 1990; 35:299–300.

19. Sherman BM, Chapler FK, Crickard K, Wycoff D. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest. 1979; 64:398–404.